SRC and lung adenocarcinoma: Pazopanib could target RIPK1 to act as a cytostatic inhibitor of necroptosis (Fauster et al., 2015), while the c-Src inhibitor Dasatinib could enhance necroptosis in paclitaxel-treated lung adenocarcinoma cells (Diao et al., 2016).